Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Nature Communications|April 25, 2020
LGR5 marks targetable tumor-initiating cells in mouse liver cancerWanlu Cao, Meng Li, Jiaye Liu, et al.
Scientific Reports|July 25, 2019
Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levelsKostandinos Sideras, Robert A de Man, Susan M Harrington, et al.
Cellular and Molecular Gastroenterology and Hepatology|September 26, 2022
GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T CellsYannick S Rakké, Lucia Campos Carrascosa, Adriaan A van Beek, et al.
Cancers|August 27, 2021
Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility StudyRogier Baak, François E J A Willemssen, Yvette van Norden, et al.
Cellular and Molecular Gastroenterology and Hepatology|September 15, 2020
Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy ResistanceJiaye Liu, Pengfei Li, Ling Wang, et al.
Antiviral Research|September 27, 2015
Modeling rotavirus infection and antiviral therapy using primary intestinal organoidsYuebang Yin, Marcel Bijvelds, Wen Dang, et al.
Oncoimmunology|March 28, 2017
PD-L1, Galectin-9 and CD8<sup>+</sup> tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinomaKostandinos Sideras, Katharina Biermann, Joanne Verheij, et al.
JHEP Reports : Innovation in Hepatology|June 23, 2026
Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohortKoen C van Son, Kirsi M A van Eekhout, Judith de Vos-Geelen, et al.
Journal of Hepatology|June 14, 2019
Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint moleculesGuoying Zhou, Dave Sprengers, Shanta Mancham, et al.
Journal for Immunotherapy of Cancer|September 9, 2020
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cellsLucia Campos Carrascosa, Adriaan A van Beek, Valeska de Ruiter, et al.
Pageof 9